Table 4.
Various Initial Treatment Strategies Based on PTLD Subtype in the Total Cohort
| Treatment Category | Nondestructive (n = 3) | Polymorphic (n = 13) | Monomorphic DLBCL Type (n = 137) | Monomorphic non-DLBCL Type (n = 37) | PTLD NOS (n = 31) | Classic Hodgkin (n = 6) | Total (n = 227) |
|---|---|---|---|---|---|---|---|
| DIS alone | 2 (66.7%) | 5 (38.5%) | 17 (12.4%) | 8 (21.6%) | 5 (16.1%) | 1 (16.7%) | 38 (16.7%) |
| Rituximab ± DIS (includes rituximab alone) | 0 | 5 (38.5%) | 47 (34.3%) | 3 (8.1%) | 8 (25.8%) | 0 | 63 (27.8%) |
| Chemotherapy ± DIS (includes chemo alone) | 0 | 0 | 45 (32.8%) | 15 (40.5%) | 4 (12.9%) | 3 (50%) | 67 (29.5%) |
| Surgery ± DIS (includes surgery alone) | 1 (33.3%) | 1 (7.7%) | 10 (7.3%) | 6 (16.2%) | 3 (9.7%) | 0 | 21 (9.3%) |
| Othera | 0 | 2 (15.4%) | 18 (13.1%) | 5 (13.5%) | 11 (35.5%) | 2 (33.3%) | 38 (16.7%) |
aInterferon +DIS, no treatment—dead before treatment initiation, observation, radiation, radiation+DIS.
DIS = decreased immunosuppression; DLBCL = diffuse large B-cell lymphoma.